Lycopene

Lycopene is the carotenoid that gives tomatoes their red color. You absorb more of it from cooked and processed tomatoes (think paste and sauce) than from raw ones. The appeal for heart health is simple on paper: lycopene is an antioxidant, and it might slow the buildup of arterial plaque. The human evidence behind that idea is thin and pulls in different directions.

How it's thought to work

Lycopene neutralizes free radicals, the reactive molecules that oxidize LDL cholesterol once it lodges in the artery wall. Verhoeven's analysis describes oxidized LDL as a driver of foam-cell formation, the early step in plaque development, so cutting LDL oxidation is the proposed mechanism by which lycopene could help [1]. This is a plausible pathway, not proof that eating more lycopene changes what happens in your arteries.

What the studies found

The observational data are suggestive but limited. Verhoeven's analysis notes that people with higher blood lycopene tend to have lower carotid intima-media thickness (CIMT), a measure of early arterial thickening [1]. That's a correlation, and it can't tell you whether lycopene caused the thinner arteries or traveled alongside other healthy habits.

One positive randomized trial ran for a year and found a significant CIMT improvement versus control [2]. The catch is in the design: participants took lycopene combined with lutein, another carotenoid. Because the two were given together, the benefit cannot be attributed to lycopene by itself. The trial supports the combination, not lycopene alone.

A separate randomized trial (Thies 2012) found no improvement in cardiovascular risk factors [3]. It ran 12 weeks, enrolled healthier, disease-free participants, and did not measure CIMT, so it tested a different question over a shorter window.

Verhoeven's reconciliation of the mismatch points to those design differences: the null trial was shorter, studied healthier people, and likely carried dietary-recall error [1]. That's a reasonable interpretation, though it's an analyst's synthesis rather than a tested conclusion.

Where that leaves lycopene

Verhoeven's bottom-line read is blunt: "Evidence is weak. Shyly points to ≥20 mg/day possibly having an effect over ≥1 year. Not worth pursuing unless you have established CVD; more potent interventions exist" [1]. Put plainly, you have a CIMT signal from a combined-supplement trial that can't be pinned on lycopene, set against a null short-term trial. That falls short of an established plaque intervention.

Dosing, as studied

Trials below roughly 20 mg/day showed no effect, so 20 mg/day is the threshold where any signal appears [1]. For food sources, tomato paste delivers about 10-30 mg per 100 g and is the most bioavailable form, with cooking improving absorption; raw tomatoes provide only about 1-7 mg per 100 g [1]. These are amounts used in or implied by the research, not a recommendation to supplement.

Where the evidence is contested

The core disagreement is whether lycopene does anything for your arteries at all.

The case for a possible effect rests on the year-long trial that showed CIMT improvement [2], supported by observational links between higher blood lycopene and lower CIMT [1]. Verhoeven argues the design differences (duration, participant health, dietary measurement) explain why a second trial came up empty [1].

The case against is the null trial itself, which found no change in cardiovascular risk factors [3], and a structural problem with the positive trial: lycopene was combined with lutein, so the benefit cannot be separated out [2]. The observational data remain correlational and can't establish cause [1].

Both points come from the same analyst (Verhoeven), who also rates the overall evidence as weak and advises against pursuing lycopene unless you already have cardiovascular disease [1]. Treat the positive signal as a reason for more study, not as settled benefit.

This article is educational and not medical advice. If you're managing heart disease or weighing supplements, talk with your clinician about interventions with stronger evidence.

References

raw/physionic/physionic-lycopene-1year-reversing-plaque.txt
Lycopene + lutein 1-year RCT — CIMT improvement (positive) · PubMed 24047757
Thies 2012 — lycopene/tomato diet RCT (12wk, n=225); NOT a CIMT study; all CV risk factor endpoints null; disease-free population "too healthy" · PubMed 22492370